Related Experiment Video

Updated: Jul 16, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Drug resistance in cancer: principles of emergence and prevention

Natalia L Komarova1, Dominik Wodarz

  • 1Department of Mathematics, 103 MSTB, University of California, Irvine, CA 92697, USA. komarova@math.uci.edu

Proceedings of the National Academy of Sciences of the United States of America
|June 28, 2005
PubMed

Insights

Cancer drug resistance often emerges before treatment begins. Mathematical modeling suggests combination therapy may not always outperform single drugs, especially for fast-growing tumors, but can help overcome resistance in specific cases like leukemia.

Area of Science:

  • Mathematical Oncology
  • Cancer Drug Resistance
  • Pharmacodynamics

Background:

  • Targeted therapies show promise in cancer treatment but face challenges due to drug resistance.
  • Understanding the principles of resistance emergence and prevention is crucial for effective cancer therapy.
  • Small-molecule drugs targeting specific oncogenes are a key component of modern cancer treatment.

Purpose of the Study:

  • To develop a mathematical framework for studying the emergence and prevention of drug resistance in targeted cancer therapy.
  • To analyze the impact of measurable parameters like tumor cell turnover and mutation rates on resistance development.
  • To explore therapeutic strategies, including combination therapy, for overcoming drug resistance.

Main Methods:

  • Development of a stochastic dynamical system model based on measurable biological parameters.
  • Analysis of tumor cell turnover rates and the generation rate of resistant mutants.
  • Application of the mathematical framework to chronic myeloid leukemia (CML) treated with imatinib.

Main Results:

  • Drug resistance primarily emerges before the initiation of targeted therapy.
  • For cancers with high cell turnover rates, combination therapy may offer limited advantage over single-drug therapy.
  • Mathematical modeling suggests that combining three targeted drugs with distinct specificities could potentially overcome resistance in CML.

Conclusions:

  • The timing of resistance emergence is a critical factor in the success of targeted cancer therapies.
  • The efficacy of combination therapy is dependent on cancer-specific parameters, such as tumor growth rate.
  • Mathematical modeling provides valuable insights into optimizing treatment strategies to combat drug resistance in cancers like CML.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...